Allurion Unveils Promising Results: Combining Allurion Program with Low-Dose GLP-1 Boosts Weight Loss and Muscle Mass

Stock Information for Allurion Technologies Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Allurion Technologies Inc.

Allurion Announces Postponement of Special Meeting of Stockholders
Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence
Allurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025
Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity
Allurion to Participate in Upcoming Investor Conferences
Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.